ClinicalTrials.gg

Program

belacabnagene franleucel

Its studies are mostly in Scleroderma, Systemic · Lupus Nephritis · Lymphoma, Mantle-Cell, led by Nkarta.

Furthest: phase 2, since Jul 10, 20243 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nkarta33 open or runningphase 2since Jul 10, 2024Aug 20, 2021Apr 2027phase 2 · NCT06557265

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2021First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05020678 · 150 enrolled · United States, Australia
  2. Jul 10, 2024Phase 2 study in Lupus NephritisNCT06557265 · 120 planned · United States, Australia, Puerto Rico
  3. Dec 4, 2024Phase 2 study in Scleroderma, SystemicNCT06733935 · 240 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 2 study in Lupus NephritisNCT06557265
  2. Oct 2028Primary completion: phase 2 study in Scleroderma, SystemicNCT06733935

TargetBeta

CD19 →IL15 →read by rule
“A preparation of off-the-shelf (OTS), allogeneic and ex vivo expanded natural killer cells (NKs) that are engineered to express membrane-bound IL-15 (mbIL15) and a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 that is coupled to the ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06733935Scleroderma, Systemic · United States2RecruitingOct 2028240
NCT06557265Lupus Nephritis · United States, Australia, Puerto Rico2RecruitingApr 2027120
NCT05020678Lymphoma, Non-Hodgkin · United States, Australia1Active, not recruitingMar 31, 2025150

How it is read

Names in the registry

  • “NKX019”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.